Anti-CEACAM6 Heavy Chain Ab
Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is a glycosylated tumor antigen anchored by glycophosphoinositol. Researchers have developed an anti-CEACAM6 antibody (TMU) using an immune llama library, which can be engineered into either a single-domain antibody (sdAb) or a heavy-chain antibody (HCAb). These anti-CEACAM6 heavy-chain antibodies are effective in detecting various cancer types, including blood cancers and solid tumors.
What are antibody-drug conjugates?
ADCs functions by targeting specific cancer cells and delivering concentrated doses of highly potent chemotherapy drugs directly into them. ADCs work by damaging or destroying the cancer cells while sparing the surrounding healthy cells.
Components of ADCs
Antibody
A monoclonal antibody that specifically targets antigens on cancer cells, ensuring precise delivery.
Payload
A potent cytotoxic (chemotherapy) drug that destroys the targeted cancer cells.
Linker
A chemical structure that connects the antibody to the payload, ensuring stable transport and controlled release of the drug at the tumor site.
What are Camelid Antibodies?
Camelid antibodies come from mammals in the Camelidae family, such as llamas, camels, and alpacas. These animals produce two primary types of antibodies. The first type is the conventional antibody, composed of two heavy chains and two light chains. The second type is known as heavy chain IgG (hcIgG), which consists of only two heavy chains and lacks the CH1 region found in conventional antibodies. Despite the absence of the CH1 region, these hcIgG antibodies retain an antigen-binding domain called the VHH region. VHH antibodies, also referred to as single-domain antibodies, are derived from this VHH region and represent a smaller, more compact form of antibody. Due to their smaller size, VHH antibodies can detect specific epitopes that might be inaccessible to traditional antibodies in techniques such as blocking assays or flow cytometry due to steric hindrance. Their compact structure also enables them to penetrate fixed tissues and enter cells more easily, facilitating more precise immunohistochemistry (IHC) staining and intracellular flow cytometry analysis. This makes VHH antibodies particularly valuable for applications requiring detailed and specific cellular or tissue-level staining.
Anti-CEACAM6 Heavy Chain Ab
CEACAM6 is a glycosylated tumor antigen involved in cancer progression, making it a promising target for cancer therapy. Researchers have developed a specialized anti-CEACAM6 antibody (TMU) using an immune llama library, which can be engineered into highly effective single-domain (sdAb) or heavy-chain antibodies (HCAb). These antibodies are designed to detect and bind to CEACAM6, allowing them to identify a wide range of cancers, including both blood cancers and solid tumors, making them valuable for cancer diagnosis and treatment strategies.
Technology Transfer From Taipei Medical University
TMU HCAb recognizes glycosylated CEACAM6 in tumor cells and demonstrates high affinity (KD < 1 nM) for the antigen (recombinant CEACAM6).
The heavy-chain antibody (TMU HCAb) specifically targets CEACAM6 in cancerous tissues.
The heavy-chain antibody (TMU HCAb) exhibits low affinity for normal tissues.
Animal Model
Toxicology
IND Timeline
